G
Gotham Therapeutics
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery
About Gotham Therapeutics
Gotham Therapeutics is pioneering a novel drug class that targets the epitranscriptomics machinery, a critical component in mRNA biology. The company operates within the biopharma sector and serves clients in the medical and pharmaceutical industries. Gotham Therapeutics leverages its transatlantic presence, with operations in New York and a subsidiary near Munich, Germany, to attract top-tier talent and academic expertise. The business model focuses on target validation, drug discovery, and development, aiming to bring groundbreaking treatments to market. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of developed drugs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- New York City, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 27.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2018 | $54M | $216M | Versant Ventures · Forbion Capital Partners · SR One | — |
| SPINOUTOther financing | Jan 2017 | $0 | — | Weill Cornell | — |
Growth signals
Latest recorded traffic for Gotham Therapeutics is 260 monthly website visits, down 72.6% over the last three months. Gotham Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gotham Therapeutics in the New York City ecosystem
The Gotham Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Versant Ventures
Forbion Capital PartnersSR One
Other known investors1 additional known investor
Weill Cornell
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gotham Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gotham Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










